Tempus AI

Genetic and oncogenic features of RASGRF fusions - npj Precision Oncology npj Precision Oncology - Genetic and oncogenic features of RASGRF fusions

Dr. Frederick Wilson + colleagues have identified RASGRF1/2 fusions across a variety of tumor types, gaining insight on incidence, structural diversity, + tissue distribution of this distinct fusion class.
🔗 www.nature.com/articles/s41... @tempusai.bsky.social

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing - The Cancer Letter Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are […]

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing (@tempusai.bsky.social‬)
https://cancerletter.com/drugs-and-targets/20250711_11a/

Unlocking the future of precision medicine: The untapped power of RNA - The Cancer Letter True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanism...

"This approach not only increases the likelihood of trial success, but also reduces the financial burden of conducting studies," write Eric Lefkofsky and Norman E. Sharpless
cancerletter.com/trials-and-t...

Looking forward to seeing you at #ASCO25! Attend our Industry Expert Theater with Kate Sasser, PhD, Ezra Cohen, MD, and Halla Nimeiri, MD, to discover how we are redefining precision oncology at scale—where our tests fuel smarter decisions and data advances care. Find more info: tempus.co/3S7WDYp

We’re excited to announce a collaboration to develop a companion diagnostic test with Verastem Oncology.

Our FDA-approved xT CDx assay is being leveraged as an investigational assay in Verastem’s global Phase 3 RAMP-301 clinical trial. Read more: tempus.co/3H3F9Kw

A young man shows a tablet screen to an older man. The headline says "Progressing cancer care." and on the bottom right "Life forward".

#NEWS: We are joining forces with @tempusai.bsky.social

By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments.

Learn more: bit.ly/43owlqa

#DataScience #Cancer #ResearchCollaboration

At #MIGlobal, Kate Sasser, PhD, our Chief Scientific Officer, participated in the "Accelerating a Healthier Future Through AI" panel." @milkeninstitute.org

Watch the full recording here: milkeninstitute.org/content-hub/...

We're on-site at #GU25! Stop by Booth #30 to meet with our team, learn more about our research in genitourinary cancers and explore our latest advancements in tech and #AI.

Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test - OncoDaily Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test / Acute Myeloid Leukemia (AML), AI, Andrew Frazier, Brett Mahon, cancer, Derick Hoskinson,

Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test

oncodaily.com/insight/temp...

#AML #AI #Cancer #MyelodysplasticSyndromes #MDS #Medicine #MyeloproliferativeNeoplasms #OncoDaily #Oncology #Health